278 related articles for article (PubMed ID: 15757862)
1. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
[TBL] [Abstract][Full Text] [Related]
2. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
5. [Study on histogenesis of enterochromaffin-like carcinoid in autoimmune atrophic gastritis associated with pernicious anemia].
Macukanović-Golubović L; Katić V; Rancić G; Milenović M; Marjanović G; Golubović Z
Vojnosanit Pregl; 2007 Aug; 64(8):543-8. PubMed ID: 17874722
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
7. Hypergastrinemia and enterochromaffin-like cell hyperplasia.
Delle Fave G; Marignani M; Moretti A; D'Ambra G; Martino G; Annibale B
Yale J Biol Med; 1998; 71(3-4):291-301. PubMed ID: 10461360
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis.
Kalkan Ç; Karakaya F; Soykan İ
Turk J Gastroenterol; 2016 Nov; 27(6):515-520. PubMed ID: 27852542
[TBL] [Abstract][Full Text] [Related]
9. Clinical aspects of ECL-cell abnormalities.
Hirschowitz BI
Yale J Biol Med; 1998; 71(3-4):303-10. PubMed ID: 10461361
[TBL] [Abstract][Full Text] [Related]
10. The gastric mucosa 25 years after proximal gastric vagotomy.
Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
[TBL] [Abstract][Full Text] [Related]
11. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.
Berna MJ; Annibale B; Marignani M; Luong TV; Corleto V; Pace A; Ito T; Liewehr D; Venzon DJ; Delle Fave G; Bordi C; Jensen RT
J Clin Endocrinol Metab; 2008 May; 93(5):1582-91. PubMed ID: 18270260
[TBL] [Abstract][Full Text] [Related]
13. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid.
Annibale B; Azzoni C; Corleto VD; di Giulio E; Caruana P; D'Ambra G; Bordi C; Delle Fave G
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1449-56. PubMed ID: 11742193
[TBL] [Abstract][Full Text] [Related]
14. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis.
Herold Z; Herold M; Nagy P; Patocs A; Doleschall M; Somogyi A
J Diabetes Investig; 2020 Jul; 11(4):865-873. PubMed ID: 31883432
[TBL] [Abstract][Full Text] [Related]
15. [Type 1 carcinoids and ECL-cell hyperplasia of the gastric mucosa].
Stachura T; Strzałka M; Bolt L
Przegl Lek; 2003; 60(12):782-8. PubMed ID: 15058016
[TBL] [Abstract][Full Text] [Related]
16. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
17. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor.
Kleveland O; Syversen U; Slørdahl K; Waldum HL
Digestion; 2001; 64(2):71-4. PubMed ID: 11684818
[TBL] [Abstract][Full Text] [Related]
18. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis.
Borch K; Stridsberg M; Burman P; Rehfeld JF
Scand J Gastroenterol; 1997 Mar; 32(3):198-202. PubMed ID: 9085454
[TBL] [Abstract][Full Text] [Related]
19. Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids.
Azzoni C; Doglioni C; Viale G; Delle Fave G; De Boni M; Caruana P; Ferraro G; Bordi C
Am J Surg Pathol; 1996 Apr; 20(4):433-41. PubMed ID: 8604810
[TBL] [Abstract][Full Text] [Related]
20. Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?
Alexandraki KI; Nikolaou A; Thomas D; Syriou V; Korkolopoulou P; Sougioultzis S; Kaltsas G
Clin Endocrinol (Oxf); 2014 May; 80(5):685-90. PubMed ID: 24118101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
